NatureForm is proud to announce the successful installation and validation of its viral incubators with Sanofi Pasteur, who predicts its flu vaccine production will triple with the use of NatureForm’s technology. This new facility will produce millions of doses of annual flu vaccine as well as help safeguard and stockpile vaccines in the event of pandemic illness. Awaiting the approval from the U.S. Food and Drug Administration, Sanofi Pasteur’s facility is projected to be online in 2008.
NatureForm’s new technology supplied to Sanofi Pasteur includes 9 spectacular incubators. Each incubator is designed specifically to hold 202,000 eggs, a grand total of 1,818,000 eggs. The incubators must pass rigorous inspection, including temperature and humidity mapping to tight specifications in order to meet their strategic protocol. These newly designed incubators have extraordinarily high biosecurity with low air particulate counts and are amazingly easy to clean.In addition to high quality products, NatureForm continues to exceed expectations by offering customized software programs, tailored to the needs of each client.
Sanofi Pasteur, a part of Sanofi-Aventis Group, contributes to $2.2 billion vaccines and is the world's largest company devoted entirely to vaccine production. Their production includes a wide range of vaccines to fight various bacterial and viral diseases.
The new facility will create approximately 100 new positions. Sanofi Pastuer said the new facility is part of its 110-year vaccine legacy. “The jobs are very well paying and when our waste water treatment plant is on line we will then be able to have another 400 jobs as they continue their expansion,” Sanofi Pasteur said.